The 2023 RRI Symposium gathered leading scientists for dynamic discussions on current topics, such as the CONVINCE trial, which concluded a lower risk of death with hemodiafiltration compared to hemodialysis, and the benefits of hemodiafiltration and exercise. A compelling review on incremental hemodialysis also introduced the ongoing TwoPlus trial. Further, the attendees got an update on morbidity and mortality in the pediatric dialysis population, learned about a clinical trial emulation of antihypertensive drugs addressing intradialytic hypotension, and about the knowledge gaps in the management of failed kidney transplant patients on dialysis. A round table event prompted a lively discussion on high-priority research areas and concluded the workshop.

Sessions

Session:

Roundtable: Questions of a young nephrologist to leaders in the field

Dr. Ana Catalina Alvarez Elias and a panel of distinguished experts for a captivating roundtable discussion, "Questions of a Young Nephrologist to Leaders in the Field," where seasoned leaders share insights and experiences that are sure to inspire and the opportunity to unlock invaluable knowledge and gain a fresh perspective.

watch now...

Speaker:

Ana Catalina Alvarez Elias, MD, MSc, PhD & Entire Faculty

Renal Research Institute, New York, NY

Session:

Patients with failed kidney transplants on HD/PD

Gain valuable insights into patients with failed kidney transplants undergoing hemodialysis (HD) or peritoneal dialysis (PD) with Dr. Neill Duncan from Imperial College, London. Explore his recorded presentation, offering a crucial session for a deeper understanding of post-transplant challenges.

WATCH NOW...

Speaker:

Neill Duncan, MD

Imperial College, London, United Kingdom

Session:

Clincal trial emulation of antihypertensive drugs in HD with intradialytic hypotension

Dr. Carmine Zoccali shares his persective on antihypertensive medications are often prescribed to manage hypertension in hemodialysis (HD) patients. Intradialytic hypotension (IDH) is a common complication in these patients. In an emulation of a randomized trial  (submitted for publication) in a cohort of 4072 incident patients who started anti-hypertensive drug treatment between January 2016 and December 2019,  we found that beta and alpha-beta-blockers, ACE inhibitors or angiotensin II antagonists, and diuretics may increase the risk of IDH in HD patients compared to calcium antagonists. The effect of beta and alpha blockers on IDH was increased in patients with a pre-dialysis fluid overload <2L.

WATCH NOW...

Speaker:

Carmine Zoccali, MD

Nephrologist & Clinical Investigator, Reggio Calabria, Italy

Session:

Morbidity and mortality of children on dialysis

Discover innovating insights from Dr. Guido Filler from Western University. Dive deep into the recorded presentation as Dr. Filler uncovers critical insights on the morbidity and mortality of children on dialysis. In this enlightening session, gain a comprehensive understanding of the pivotal aspects shaping pediatric nephrology.

WATCH NOW...

Speaker:

Guido Filler, MD, PhD, FRCPC

Paediatric Nephrology at Western University, London, Ontario, Canada

Session:

Roundtable: Unmet research needs in hemodialysis

Explore the recorded roundtable discussion featuring the renowned Dr. John Daugirdas from the University of Illinois at Chicago and a panel of esteemed faculty as they uncover the unmet research needs in hemodialysis that can reshape the future of patient care. This insightful discussion offers a unique perspective on challenges and opportunities in our field

WATCH NOW...

Speaker:

John Daurigdas, MD, FASN & Entire Faculty

Renal Research Institute, New York, NY

Session:

Incremental HD

Examine the world of Incremental Hemodialysis (HD) with Dr. Mariana Murea from Wake Forest University. Gain valuable insights into the latest advancements and strategies in renal care that can reshape your practice.

WATCH NOW...

Speaker:

Mariana Murea, MD

Wake Forest University

Session:

The CONVINCE trial: what have we learned, what is still open?

Uncover the latest findings from the recorded presentation featuring Dr. Peter Blankestijn and Krister Cromm as they dissect "The CONVINCE Trial: What Have We Learned, What Is Still Open?" Dr. Blankestijn from the University Medical Center in Utrecht expertly summarizes the results, while Krister Cromm from Fresenius Medical Care’s Biomedical Evidence Generation team sheds light on patient outcomes.

WATCH NOW...

Speaker:

Peter Blankestijn, MD, PhD & Krister Cromm, MA, MBA, MSc

UMC Utrecht, The Netherlands; FMC

Session:

Experience with HDF and exercise during dialysis

Delve into the future of renal research with Dr. Magdalena Madero! Explore the realm of High-Volume Hemodiafiltration (HDF) and the transformative impact of exercise during dialysis in this exclusive recorded presentation from the Renal Research Institute Symposium. Gain insights, stay updated, and elevate your nephrology practice with the brilliant Dr. Madero.

WATCH NOW...

Speaker:

Magdalena Madero, MD

Instituto Nacional de Cardiologia Ignacio Chavez; Mexico City